Controlled Crystallization During Freeze-Drying - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Controlled Crystallization During Freeze-Drying
The authors discuss the preparation of lipophilic drug nanocrystals by controlled crystallization during freeze-drying.

Pharmaceutical Technology
Volume 35, Issue 8, pp. 58-62


By using in-line Raman spectroscopy, it was shown that during the freezing step of the CCDF process only the solvents crystallized. The solutes did not crystallize until the temperature in the freeze-dryer was increased. Furthermore, the three-way nozzle can be used to alter the small-batch process into a semicontinuous process that is suitable for large-scale production. Controlled crystallized dispersions prepared by the semicontinuous process results in even smaller nanocrystals due to a higher freezing rate. Therefore, the semicontinuous process is not only suitable for large-scale production, but can also result in a better product.

Hans de Waard* is postdoctoral researcher, Niels Grasmeijer is a doctoral student, Wouter L.J. Hinrichs is senior researcher, and Professor Henderik W. Frijlink is chairman, all at the Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands, tel. +31 50 363 2397, fax +31 50 363 2500,
. Professor Thomas De Beer is a professor in the Laboratory of Pharmaceutical Process Analytical Technology at the Department of Pharmaceutical Analysis, Ghent University.

*To whom all correspondence should be addressed.

Submitted: Feb. 11, 2011. Accepted: Apr. 27, 2011.


1. C.A. Lipinski et al., Adv. Drug Deliv. Rev. 46 (1–3), 3–26 (2001).

2. G.L. Amidon et al., Pharm. Res. 12 (3), 413–420 (1995).

3. W. Curatolo, Pharm. Sci. Tech. Today 1 (9), 387–393 (1998).

4. D. Hou et al., Biomaterials 24 (10), 1781–1785 (2003).

5. A.A. Noyes and W.R. Whitney, J. Am. Chem. Soc. 19 (12), 930–934 (1897).

6. C.M. Keck and R.H. Muller, Eur. J. Pharm. Biopharm. 62 (1), 3–16 (2006).

7. B.Y. Shekunov et al., Pharm. Res. 23 (1), 196-204 (2006).

8. H. de Waard, W.L.J. Hinrichs, and H.W. Frijlink, J. Control. Release 128 (2), 179–183 (2008).

9. D.J. van Drooge, W.L.J. Hinrichs, and H.W. Frijlink, J. Pharm. Sci. 93 (3), 713–725 (2004).

10. R.L. McCreery, Raman Spectroscopy for Chemical Analysis, (Wiley-Interscience, New York, 1st ed., 2000).

11. H. de Waard et al., Eur. J. Pharm. Sci. 38 (3), 224–229 (2009).

12. J. Hu et al., Pharm. Res. 19 (9), 1278-1284 (2002).

13. M.J. Pikal, "Freeze drying" in Encyclopedia of Pharmaceutical Technology, J. Swarbrick, ed. (New York, Informa Healthcare USA, 2007).

*This article is based on a presentation given at the 7th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology (PBP World Meeting) in Malta 2010.

Citation: When referring to this article, please cite it as "H. de Waard, N. Grasmeijer, W.L.J. Hinrichs, T. De Beer, H.W. Frijlink, "Controlled Crystallization During Freeze-Drying," Pharmaceutical Technology 35 (8) 58-62(2011)."


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here